Keapstone Therapeutics
Keapstone Therapeutics is a biotech company that develops drugs targeting the Nrf2 signaling pathway for neuroprotection in conditions such as Parkinson's disease and motor neuron disease. The company utilizes research from the University of Sheffield and collaborates with Parkinson's UK for expertise and funding.
- Small molecule activators of the Nrf2-ARE pathway
- Neuroprotective therapies for Parkinson's and motor neuron disease
Locations
Digital Popularity
Social Media
Company Details
Keapstone Therapeutics is operated by Keapstone Therapeutics Limited and is a Active company incorporated on 1 February 2017 with the registered office located in Sheffield, South Yorkshire. Keapstone Therapeutics Limited was registered 8 years ago.
Status
Active
Size
Micro
Directors
4
Age
8 years old
Employees
Unreported
Turnover
Unreported
Total Assets
£148.54K
Cash in Bank
Unreported
Total Liabilities
-£286.74K